The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium

Journal of Pharmacological and Toxicological Methods

Volumn 75, Issue , 2015, Pages 70-90

  Guth, Brian D ^a   Chiang, Alan Y ^b   Doyle, Jennifer ^c   Engwall, Michael J ^d   Guillon, Jean Michel ^e   Hoffmann, Peter ^c   Koerner, John ^f   Mittelstadt, Scott ^g   Ottinger, Sean ^c   Pierson, Jennifer Beck ^c   Pugsley, Michael K ^c   Rossman, Eric I ^h   Walisser, Jacqueline ^c   Sarazan, R Dustan ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c Data Sciences International ^*  (United States)

^d AMGEN INC   (United States)

^e SANOFI   (France)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g ABBVIE INC   (United States)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Amrinone; Arterial blood pressure; Atenolol; Beagle dog; Contractility; Heart rate; Itraconazole; Left ventricular dP dt; Myocardial; Pimobendan

Indexed keywords

AMRINONE; ATENOLOL; ITRACONAZOLE; PIMOBENDAN; PYRIDAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; BEAGLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROCARDIOGRAPHY; FEMALE; HEART AFTERLOAD; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART PRELOAD; HEART RATE; INOTROPISM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BLOOD PRESSURE; DOG; DRUG EFFECTS; HEART CONTRACTION; PROCEDURES; TELEMETRY;

AMRINONE; ANIMALS; ATENOLOL; BLOOD PRESSURE; DOGS; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; ITRACONAZOLE; MALE; MYOCARDIAL CONTRACTION; PYRIDAZINES; TELEMETRY;

EID: 84942549502     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2015.02.002     Document Type: Article

References (30)

1. Ahmad S.R., Singer S.J., Leiss B.G. Congestive heart failure associated with itraconazole. Lancet 2001, 357:1766-1767.
2. Alousi A.A., Johnson D.C. Pharmacology of the bipyridines: Amrinone and milrinone. Circulation 1986, 73(3 Pt 2):10-24. (III).
3. Anon. ICHS7A: Safety pharmacology studies for human pharmaceuticals. Federal Register 2001, 66. (36791-3679).
4. Atkins C., Bonagura J., Ettinger S., Fox P., Gordon S., Haggstrom J., et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. Journal of Veterinary Internal Medicine 2009, 23(6):1142-1150.
5. Chiang A.Y., Bass A.S., Cooper M.M., Engwall M.J., Menton R.G., Thomas K. ILSI-HESI cardiovascular safety subcommittee dataset: An analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc). Journal of Pharmacological and Toxicological Methods 2007, 56:95-102.
6. Chiang A.Y., Smith W.C., Main B.W., Sarazan R.D. Statistical power analysis for hemodynamic cardiovascular safety pharmacology studies in beagle dogs. Journal of Pharmacological and Toxicological Methods 2004, 50:121-130.
7. Chu K.-M., Hu O.Y., Shieh S.-M. Cardiovascular effect and simultaneous pharmacokinetic and pharmacodynamics modeling of pimobendan in health normal subjects. Drug Metabolism and Disposition 1999, 27:701-709.
8. de Abreu L.R., de Castro S.A., Pedrazzoli J. Atenolol quantification in human plasma by high-performance liquid chromatography: Application to bioequivalence study. AAPS PharmSci 2003, 5(2):116-122.
9. Hamlin R.L., del Rio C. dP/dt(max)-A measure of 'baroinometry'. Journal of Pharmacological and Toxicological Methods 2012, 66(2):63-65.
10. Hardin T.C., Grybill J.R., Fetchick R., Woestenborghs R., Rinaldi M.G., Kuhn J.G. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrobial Agents and Chemotherapy 1988, 32(9):1310-1313.
11. Henriques T.A., Beck T.W., Douglas C.L., Jones H.M., Kremer J.J., Kruzich P.J., et al. Left thoracotomy surgical approach for chronic instrumentation in dogs and monkeys providing high-quality electrocardiogram signals. Journal of Pharmacological and Toxicological Methods 2010, 162:136-142.
12. Kato K. Clinical efficacy and safety of pimobendan in treatment of heart failure - Experience in Japan. Cardiology 1997, 88(Suppl. 2):28-36.
13. Klumpp A., Trautman T., Markert M., Guth B. Optimizing the experimental environment for dog telemetry studies. Journal of Pharmacological and Toxicological Methods 2006, 54:141-149.
14. Kullberg M.P., Freeman G.B., Biddlecome C., Alousi A.A., Edleson J. Amrinone metabolism. Clinical Pharmacology and Therapeutics 1981, 29(3):394-401.
15. Markert M., Klummp A., Trautmann T., Mayer K., Stubhan M., Guth B. The value added by measuring myocardial contractility "in vivo" in safety pharmacology profiling of drug candidates. Journal of Pharmacological and Toxicological Methods 2007, 56:203-211.
16. Maso D.T., Braunwald E., Covell J.W., Sonnenblick E.H., Ross J. Assessment of cardiac contractility the relation between the rate of pressure rise and ventricular pressure during isovolumic systole. Circulation 1971, XLIV:47-58.
17. Norton K., Iacono G., Vezina M. Assessment of the pharmacological effects of inotropic drugs on the left ventricular pressure and contractility: An evaluation of the QA interval as an indirect indicator of cardiac inotropism. Journal of Pharmacological and Toxicological Methods 2009, 60:193-197.
18. Qu Y., Fang M., Gao B., Amouzadeh H.R., Li N., Narazanan P., et al. Itraconazole decreases left ventricular contractility in isolated rabbit heart: Mechanism of action. Toxicology and Applied Pharmacology 2013, 268:113-122.
19. Sarazan R.D. Cardiovascular pressure measurement in safety assessment studies: Technology requirements and potential errors. Journal of Pharmacological and Toxicological Methods 2014, 70(3):210-223. 10.1016/j.vascn.2014.06.003.
20. Sarazan R.D., Kroehle J.P., Main B.W. Left ventricular pressure, contractility and dP/dtmax in nonclinical drug safety assessment studies. Journal of Pharmacological and Toxicological Methods 2012, 66:71-78.
21. Sarazan R.D., Mittelstadt S., Guth B., Koerner J., Zhang J., Pettit S. Cardiovascular function in nonclinical drug safety assessment: Current issues & opportunities. International Journal of Toxicology 2011, 30(3):272-286.
22. Sivarajah A., Collins S., Sutton M.R., Regan N., West H., Holbrook M., et al. Cardiovascular safety assessments in the conscious telemetered dog: Utilisation of super-intervals to enhance statistical power. Journal of Pharmacological and Toxicological Methods 2010, 62:12-19.
23. Slordal L., Spigset O. Heart failure induced by non-cardiac drugs. Drug Safety 2006, 29(7):567-586.
24. Suga H., Sagawa K., Shoukas A.A. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circulation Research 1973, 32(3):314-322.
25. Thomas S.H., Cooper R.C., Ekwuru M., Fletcher S., Gilbody J., Husseyin T.S., et al. Differential cardiovascular effects of propranolol, atenolol, and pindolol measured by impedance cardiography. European Journal of Clinical Pharmacology 1992, 42:47-53.
26. Van Meel J.C.A., Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. Journal of Cardiovascular Pharmacology 1989, 14(Suppl. 29):S1-S6.
27. Ward A., Brogden R.N., Heel R.C., Speight T.M., Avery G.S. Amrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1983, 26(6):468-502.
28. Weiss J.L., Frederiksen J.W., Weisfeldt M.L. Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. Journal of Clinical Investigation 1976, 58(3):751-760.
29. Zimmer H.G. Who discovered the Frank-Starling mechanism?. News in Physiological Sciences 2001, 17:181-184.
30. Zimpfer M., Vatner S. Effects of acute increase in left ventricular preload on indices of myocardial function in conscious, unrestrained and intact, tranquilized baboons. Journal of Clinical Investigation 1981, 67:430-438.